Trial Profile
A 12 Week Double-blind, Randomised, Placebo-controlled, Modified Dose-escalation Trial to Investigate Safety, Efficacy, and Pharmacokinetics of BIRT 2584XX Tablets at Doses of 100, 300 and 500 mg Administered Once Daily in Patients With Moderate to Severe Psoriasis With a 12 Week Treatment Extension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs BIRT 2584 XX (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 08 Oct 2009 New trial record.